Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indacaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 10/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SRSF6 | Q13247 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indacaterol SCHEMBL29350045 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29367297 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29798949 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL48098 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL159597 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867571 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL3664612 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012030 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867570 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012026 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| EP-1183240-B1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | THE BROAD INSTITUTE, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | THE BROAD INSTITUTE, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3247693-B1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| EP-3347345-B1 | MIXED SOLVATE OF (R)-5-[2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-1H-QUINOLIN-2-ONE L-TARTRATE | INKE SA (ES) | 2019-07-31 | — | — | EP | disclosed |
| US-10227305-B2 | Process for preparing indacaterol and salts thereof | REDDY, G. Pratap (IN) | 2019-03-12 | — | — | US | disclosed |
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | REDDY, G. Pratap (IN) | 2018-08-02 | — | — | US | disclosed |
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | REDDY, G. Pratap (IN) | 2018-08-02 | — | — | US | disclosed |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2017-12-21 | — | — | US | disclosed |
| WO-2016116857-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016027283-A2 | A PROCESS FOR PREPARING INDACATEROL AND SALTS THEREOF | REDDY G PRATAP (IN) | 2016-02-25 | — | — | WO | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | CYP11B1, CYP4A11, CYP17A1 | ADRB2 181/4885ADRB1 109/4885SLC6A2 2324/4885 |
| US-10227305-B2 | Process for preparing indacaterol and salts thereof | CYP4A11, HSD17B7, CYP17A1 | ADRB2 173/4885ADRB1 107/4885SLC6A2 1880/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | ADRB2 552/4885ADRB1 435/4885SLC6A2 287/4885 |
| US-20170362161-A1 | PROCESS FOR THE PREPARATION OF INDANAMINE DERIVATIVES AND NEW SYNTHESIS INTERMEDIATES | CYP3A5, SQLE, CYP3A4 | ADRB2 83/4885ADRB1 61/4885SLC6A2 665/4885 |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | ADRB2 4023/4885ADRB1 3643/4885SLC6A2 4383/4885 |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | RAB5IF, LIPA, CLTB | ADRB2 3873/4885ADRB1 3350/4885SLC6A2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.